The NICE recommends the use of finerenone (10 & 20mg) as a treatment option for CKD associated with T2D in adults
The recommendation was based on the P-III study (FIDELIO-DKD) evaluating finerenone vs PBO in 5734 adult patients which showed a reduction in risk of the primary composite renal outcome of time to kidney failure, a decrease of eGFR ≥ 40% from baseline over 4wks. or death from renal causes by 18% (relative & absolute risk reduction 3.3%) over a median duration of follow-up of 2.6yrs., (17.8% vs 21.1%) experienced a primary composite renal outcome when added to an MTD of an ACE inhibitor or ARB
14% relative risk reduction in key secondary cardiovascular EPs, 13% vs 14.8% experienced a key secondary cardiovascular event over a median duration of 2.6yrs. follow-up
Ref: Pharmiweb | Image: Bayer
Related News:- Bayer’s Kerendia (finerenone) Receives Health Canada’s Approval for the Treatment of Chronic Kidney Disease and Type 2 Diabetes
